Valeant Pharmaceuticals International, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: April 15, 2019
Pages: 50
US$ 499.00
Valeant Pharmaceuticals International, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)

Download PDF Leaflet

Valeant Pharmaceuticals International, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Valeant Pharmaceuticals International, Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Valeant Pharmaceuticals International, Inc. and its competitors. This provides our Clients with a clear understanding of Valeant Pharmaceuticals International, Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Valeant Pharmaceuticals International, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Valeant Pharmaceuticals International, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Valeant Pharmaceuticals International, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Valeant Pharmaceuticals International, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Valeant Pharmaceuticals International, Inc. business.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc., a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products principally in the United States and Canada. The company also provides research, development and clinical contract research services to third parties.

Products Portfolio

Wellbutrin XL (bupropion hydrochloride extended release tablets): Wellbutrin XL is an extended-release formulation of bupropion indicated for the treatment of depression in adults.

In 2009, the company acquired the full U.S. commercialization rights to Wellbutrin XL from The GlaxoSmithKline Group of Companies (GSK). The Wellbutrin XL product formulation was developed, and is manufactured, by the company under its own patents and proprietary technology.

Xenazine (tetrabenazine): Xenazine is indicated for the treatment of chorea associated with Huntington's disease. Huntington's disease is a rare, inherited neurological disorder that is passed from parent to child through a gene mutation. Tetrabenazine is approved for use in various countries in Europe and worldwide. Through its acquisition of the worldwide development and commercialization rights to tetrabenazine in 2009, the company has distribution arrangements for tetrabenazine in various countries outside North America, including Australia, Denmark, France, Germany, Ireland, Israel, Italy, New Zealand, Portugal, Spain, Switzerland, and the United Kingdom.

Aplenzin (bupropion hydrobromide): Aplenzin is an extended-release formulation of bupropion hydrobromide for the treatment of major depressive disorder. The company has a supply-and-distribution agreement with sanofi-aventis U.S., which is marketing the product in the U.S. Under the terms of the agreement, the company manufactures, supplies, and sells Aplenzin to sanofi-aventis U.S.

Zovirax Ointment/Zovirax Cream (acyclovir): Zovirax Ointment is a topical formulation of a synthetic nucleoside analogue which is active against herpes viruses. Each gram of Zovirax Ointment contains 50 mg of acyclovir in a polyethylene glycol base. This product is indicated for the management of initial genital herpes and in limited non-life threatening mucocutaneous herpes simplex infections in immuno-compromised patients. Zovirax Cream is a topical antiviral medication used for the treatment of herpes labialis (cold sores).

Ultram ER (tramadol hydrochloride extended-release tablets): Ultram ER is an extended-release formulation of tramadol hydrochloride indicated for the management of moderate to moderately severe chronic pain in adults. Ultram ER is available in 100mg, 200mg and 300mg tablet strengths.

In April 2009, the company has a supply agreement with Patriot Pharmaceuticals LLC (Patriot) (a wholly owned subsidiary of Ortho-McNeil-Janssen Pharmaceuticals, Inc.) for the distribution of its authorized generic formulation of Ultram ER and concurrently with the November 2009 generic launch of the 100mg and 200mg strengths of Ultram ER in the U.S., Patriot launched its authorized generic formulation of these two strengths of Ultram ER.

Cardizem LA (diltiazem): Cardizem branded products are calcium-channel blockers (CCBs). Cardizem LA is a graded, extended-release formulation of diltiazem hydrochloride that provides 24-hour blood pressure control with a single daily dose and offers physicians a dosing range from 120 mg to 540 mg.

Legacy Products

This category includes products that the company distributes in the U.S., but do not actively promote. The products in this category are Cardizem CD, Ativan, Tiazac, Vasotec, Vaseretic and Isordil.

Cardizem CD (diltiazem): Cardizem branded products are medications in the CCB category of cardiovascular drugs. sanofi-aventis Inc. (sanofi-aventis) supplies Cardizem CD to the company.

Ativan (lorazepam): Ativan is benzodiazepine lorazepam, indicated for the management of anxiety disorders or for the short-term relief of anxiety or anxiety associated with symptoms of depression.

Tiazac (diltiazem): The company acts as the manufacturer of the product. Forest distributes a Tiazac Authorized Generic manufa

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Valeant Pharmaceuticals International, Inc. Direct Competitors
5.2. Comparison of Valeant Pharmaceuticals International, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Valeant Pharmaceuticals International, Inc. and Direct Competitors Stock Charts
5.4. Valeant Pharmaceuticals International, Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Valeant Pharmaceuticals International, Inc. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Valeant Pharmaceuticals International, Inc. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Valeant Pharmaceuticals International, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Valeant Pharmaceuticals International, Inc. Major Shareholders
Valeant Pharmaceuticals International, Inc. History
Valeant Pharmaceuticals International, Inc. Products
Revenues by Segment
Revenues by Region
Valeant Pharmaceuticals International, Inc. Offices and Representations
Valeant Pharmaceuticals International, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Valeant Pharmaceuticals International, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Valeant Pharmaceuticals International, Inc. Capital Market Snapshot
Valeant Pharmaceuticals International, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Valeant Pharmaceuticals International, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Valeant Pharmaceuticals International, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Valeant Pharmaceuticals International, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Valeant Pharmaceuticals International, Inc. 1-year Stock Charts
Valeant Pharmaceuticals International, Inc. 5-year Stock Charts
Valeant Pharmaceuticals International, Inc. vs. Main Indexes 1-year Stock Chart
Valeant Pharmaceuticals International, Inc. vs. Direct Competitors 1-year Stock Charts
Valeant Pharmaceuticals International, Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Valeant Pharmaceuticals International, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: